Reprint: The Sibling Sexual Behaviour Mapping Tool (SSBMT): Supporting practitioner confidence, planning and competency when responding to sexual behaviours between siblings.

Objectives: This paper outlines the development and initial pilot of the Sibling Sexual Behaviour Mapping Tool (SSBMT). Building on the findings of the National Project on Sibling Sexual Abuse (King-Hill, McCartan, et al., 2023) and work by Yates and Allardyce (2023), the tool was devised with the aim of supporting frontline child-protection social workers during the initial stages of working with families where sibling sexual behaviours (SSB) may be present.

The Sibling Sexual Behaviour Mapping Tool (SSBMT): Supporting practitioner confidence, planning and competency when responding to sexual behaviours between siblings.

Objectives: This paper outlines the development and initial pilot of the Sibling Sexual Behaviour Mapping Tool (SSBMT). Building on the findings of the National Project on Sibling Sexual Abuse (King-Hill, McCartan, et al., 2023) and work by Yates and Allardyce (2023), the tool was devised with the aim of supporting frontline child-protection social workers during the initial stages of working with families where sibling sexual behaviours (SSB) may be present.

Physician Awareness of the Safe Use of Cyproterone Acetate in Europe: A Survey on the Effectiveness of Additional Risk Minimization Measures.

Background: Cyproterone acetate (CPA) is a synthetic progesterone derivative introduced in the 1970s and prescribed as antiandrogenic therapy for inoperable prostate cancer, sexual deviations in men, and signs of androgenization in women. In 2020, the CPA summary of product characteristics (SmPC) was revised to include an updated special warning and precaution about (1) the risk of meningioma with increasing cumulative dose and (2) contraindication in patients with meningioma or history of meningioma. A Direct Healthcare Professional Communication (DHPC) was distributed.

Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting.

Introduction: At the time of dapagliflozin's approval in Europe (2012) to treat patients with type 2 diabetes mellitus, concerns regarding acute liver injury and severe complications of urinary tract infection (sUTI) led to two post-authorization safety (PAS) studies of these outcomes to monitor the safety of dapagliflozin in real-world use.

Objective: To investigate the incidence of hospitalization for acute liver injury (hALI) or sUTI (pyelonephritis or urosepsis) among patients initiating dapagliflozin compared with other glucose-lowering drugs (GLDs).

Methods: These two noninterventional cohort studies identified initiators of dapagliflozin and comparator GLDs in November 2012-February 2019 using data from three longitudinal, population-based data sources: Clinical Practice Research Datalink (UK), the HealthCore Integrated Research Database (USA), and the Medicare database (USA).

Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting.

Introduction: Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor approved to treat type 2 diabetes mellitus (T2DM), among other conditions. When dapagliflozin was approved in Europe for treating T2DM (2012), potential safety concerns regarding its effect on kidney function resulted in this post-authorization safety study to assess hospitalization for acute kidney injury (hAKI) among dapagliflozin initiators in a real-world setting.

Objective: The aim of this study was to evaluate the incidence of hAKI in adults with T2DM initiating dapagliflozin compared with other glucose-lowering drugs (GLDs).